ArticleWorld journal of psychiatry2025
Risk of neurological and psychiatric diagnoses in COVID-19 survivors: A multicenter retrospective cohort study using electronic health records.
Article in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe neurological and psychiatric sequelae of coronavirus disease 2019 (COVID-19) have been documented, yet further data are needed to thoroughly evaluate the impact of COVID-19 on brain health years after the infection.
aimTo examine whether COVID-19 infection is associated with exacerbation, recurrence, or progression of pre-existing neurological or psychiatric disorders - a high-risk population that is underrepresented in COVID-19 outcome research in National Guard Health Affair patients in 4-years following a COVID-19 diagnosis.
methodsFor this multicenter retrospective cohort study, we used data from the National Guard hospitals electronic health records network (BestCare) with over 10 million patients. Our cohort comprised patients who had a COVID-19 diagnosis; a matched control cohort included patient did not expose to COVID-19 in same period. Age and sex were matching factors. We estimated the incidence of 14 neurological and psychiatric outcomes in nearly 4 years after a confirmed diagnosis of COVID-19. Using a multiple logistic regression, we compared incidences with those in propensity score-matched cohorts of patients with no exposure to COVID-19.
resultsOur primary cohort comprised 4437 patients diagnosed with COVID-19, and our propensity-score 1:1 matched control cohort comprised 4437 individuals. Nearly two-third of the COVID-19 cohort (71%) were diagnosed in 2020, and 2021. The most prevalent diagnoses for both cohorts were epilepsy 30.68%, mood disorder 23.92%, and nerve plexus disorder 22.13%. Dementia was nearly 4 times higher among COVID-19 cohort (8.27%) compared to the control cohort (2.57%). Five neurological and psychiatric outcomes had odds ratios (OR) that were significantly higher than 1 for people who had COVID-19 compared to people who had never been infected. These outcomes were cognitive deficit OR = 1.54, 95% confidence interval (CI): 1.23-1.91,
conclusionThe study highlights the persistent risk of neurological and psychiatric conditions in COVID-19 survivors up to four years post-infection. Although the incidence was lower than in previous large studies, long-term consequences remain significant, emphasizing the need for ongoing monitoring and support in mental health and neurological care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.